|
CA1076114A
(fr)
*
|
1975-02-10 |
1980-04-22 |
Mitsubishi Chemical Industries Limited |
Derives de 1,5-alkylene-3-arylhydantone
|
|
DE2514992A1
(de)
*
|
1975-04-05 |
1976-10-14 |
Bayer Ag |
Fungizide mittel
|
|
US4175198A
(en)
*
|
1976-10-07 |
1979-11-20 |
W. R. Grace & Co. |
5-Secondary alkylidene hydantoins
|
|
US4152445A
(en)
*
|
1976-12-18 |
1979-05-01 |
Beecham Group Limited |
1-(3-Hydroxyalk-1-yl)-5-(carboxyalkyl)hydantoin derivatives
|
|
MC1220A1
(fr)
*
|
1977-10-28 |
1979-07-20 |
Hoffmann La Roche |
Nouveaux derives d'imidazolidine
|
|
DE3213140A1
(de)
*
|
1982-04-08 |
1983-10-20 |
Celamerck Gmbh & Co Kg, 6507 Ingelheim |
Cycloalkan-5'-spiro-hydrantoine, ihre herstellung und verwendung
|
|
DE3382406D1
(de)
*
|
1982-04-08 |
1991-10-17 |
Shell Int Research |
Neue hydantoine, ihre herstellung und verwendung.
|
|
US4464387A
(en)
*
|
1982-08-06 |
1984-08-07 |
Buffalo Color Corp. |
Insecticidal phenyl hydantoin compounds
|
|
US4473393A
(en)
*
|
1982-08-06 |
1984-09-25 |
Buffalo Color Corporation |
Pesticidal thiohydantoin compositions
|
|
US4746755A
(en)
*
|
1986-05-06 |
1988-05-24 |
The Dow Chemical Company |
Preparation of hydrantoic acids and hydantoins
|
|
FR2619381B1
(fr)
*
|
1987-08-13 |
1989-12-08 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
|
|
FR2693461B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
|
US5411981A
(en)
*
|
1991-01-09 |
1995-05-02 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
|
US5593993A
(en)
*
|
1991-08-02 |
1997-01-14 |
Medivir Ab |
Method for inhibition of HIV related viruses
|
|
FR2694290B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
|
FR2741346B1
(fr)
*
|
1995-11-16 |
1997-12-19 |
Roussel Uclaf |
Nouveau procede de preparation de derives phenylimidazolidine
|
|
JP2004509072A
(ja)
*
|
2000-06-28 |
2004-03-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
|
|
US7001911B2
(en)
|
2000-06-28 |
2006-02-21 |
Bristol-Myers Squibb Company |
Fused cyclic modulators of nuclear hormone receptor function
|
|
US20040077605A1
(en)
|
2001-06-20 |
2004-04-22 |
Salvati Mark E. |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
US6953679B2
(en)
|
2000-09-19 |
2005-10-11 |
Bristol-Myers Squibb Company |
Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
|
|
EP1854798A3
(fr)
|
2000-09-19 |
2007-11-28 |
Bristol-Myers Squibb Company |
Composés de succinimide hétérocyclique fondu et leurs analogies, modulateurs de la fonction de récepteur d'hormone nucléaire
|
|
US20040087548A1
(en)
|
2001-02-27 |
2004-05-06 |
Salvati Mark E. |
Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
AU2002364082A1
(en)
|
2001-12-19 |
2003-07-09 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
NZ572374A
(en)
|
2006-03-29 |
2011-12-22 |
Univ California |
Diarylthiohydantoin compounds
|
|
EP2220050A2
(fr)
|
2007-10-26 |
2010-08-25 |
The Regents Of The University Of California |
Composés de diarylhydantoïne
|
|
CN115737643A
(zh)
|
2012-09-26 |
2023-03-07 |
阿拉贡药品公司 |
用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
|
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
|
MX2020003845A
(es)
|
2017-10-16 |
2020-11-06 |
Aragon Pharmaceuticals Inc |
Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
|